|
"Establishing Excellence in Diagnostic Innovation"
October 3rd, 2006
9:00 a.m. - 4:30 p.m. EDT
RSVP: Michelle Hickman 858-805-2419 or
mhickman@biosite.com
This event will be webcasted. Click here for the webcast registration page.
Agenda*
| 9:00 a.m. |
Introduction
Kim Blickenstaff, Chairman & CEO
Norman Paradis, M.D.,VP, Medical Affairs
|
| 9:15 a.m. |
Corporate Strategy - An Overview
Kim Blickenstaff, Chairman &
CEO
Ken Buechler, Ph.D., President & CSO |
| 10:00 a.m. |
Hospital & Laboratory Trends and Outcomes -
Moderated Panel
Norman Paradis, M.D.,VP, Medical Affairs -
Moderator
John Myers, M.D., FACEP, FAAP, President, QuestCare/HCA
Jim Jarnot, Director of Labs, Catholic Healthcare System,
Buffalo
Richard Aghababian, M.D., FACEP, University of
Massachusetts Memorial Health Care |
|
Break |
|
| 12:00 p.m. |
FDA Regulation of
In Vitro Diagnostics
Janice Hogan, Hogan & Hartson LLP |
| 12:45 p.m. |
Strategic & Global Product Marketing
Winton Gibbons, SVP, Strategic & Global
Product Marketing |
| 1:30 p.m. |
Sepsis - Market
Overview and Commercialization Strategy
Mitchell Levy, M.D., FCCM, FCCP Brown University/Rhode Island
Hospital
Erik Verhoef, Director, Market Analysis & Research
Winton Gibbons, SVP, Strategic & Global
Product Marketing |
| Break |
|
| 3:00 p.m. |
Acute Kidney Injury -
Market Overview and Commercialization Strategy
Prasad Devarajan, M.D., Cincinnati Children's Hospital
Medical Center
Erik Verhoef, Director, Market Analysis & Research
Winton Gibbons, SVP, Strategic & Global
Product Marketing |
| 4:15 p.m. |
Closing Remarks
Kim Blickenstaff, Chairman & CEO |
|
Reception With Speakers and Management
* Times are subject to change
|
|